Spots Global Cancer Trial Database for STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors
Official Title: Phase I Trial of STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematological Malignancies and Patients With Solid Tumors
Study ID: NCT00088101
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the safety, toxicity and patient tolerance of STA-5312 administered intravenously to patients with relapsed or refractory hematological malignancies and patients with solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Wilshire Oncology Medical Group, Pamona, California, United States
Baptist Cancer Institute, Jacksonville, Florida, United States
University of Chicago, Chicago, Illinois, United States
Tufts New England Medical Center, Boston, Massachusetts, United States
Newark Beth Israel Medical Center, Newark, New Jersey, United States
Carolinas HealthCare System, Charlotte, North Carolina, United States
The West Clinic, Memphis, Tennessee, United States
The Sarah Cannon Cancer Center, Nashville, Tennessee, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
